Business, energy, technology, markets and global industry news from Business News Today

Center for Drug Evaluation

PharmaDeviceNews Center for Drug Evaluation
Kelun-Biotech’s investigational dual-payload antibody-drug conjugate SKB565 advances toward Phase 1/2 clinical testing for advanced solid tumors following a China clinical trial notice. Representative image.
Pharma & Biotech

SKB565 clinical trial: Why Kelun-Biotech’s first dual-payload ADC matters

Kelun-Biotech’s SKB565 gains China clinical trial clearance, moving its first dual-payload ADC toward a Phase 1/2 solid-tumor study.

Read More
Lynk Pharmaceuticals completes patient enrollment in the Phase III zemprocitinib trial evaluating the oral JAK1 inhibitor for active ankylosing spondylitis. Representative image.
Pharma & Biotech

What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline

Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.

Read More
Representative image of a dermatology consultation and treatment planning, used to illustrate Lynk Pharmaceuticals’ zemprocitinib New Drug Application acceptance in China for moderate-to-severe atopic dermatitis.
Pharma & Biotech

Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?

Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.

Read More